BIO-PREDISC-TIA SWISS Cohort Study

Cerebrovascular Disease, Ischemic Stroke Clinical Trial

— PREDISC  

Official title:

BIOmarkers and PREDISC Diagnostic Evaluation for Patients With Suspected Transient Ischemic Attacks: the BIOPREDISC- TIA SWISS Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03994003
• Other study ID #: EOC.NSISU.4.12.99
• Status: Completed
• Start date: August 4, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: April 2024
• Source: Ospedale Civico, Lugano
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting <24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.

• At least 18 years old.

• Having given their Informed Consent.

Exclusion Criteria:

• · Patients with ocular TIA (Amaurosis fugax).

• Patients that still have neurological deficits at the moment of inclusion.

• Contraindication to perform MRI.

• For women: pregnancy.

Related Conditions & MeSH terms

• Cerebrovascular Disease, Ischemic Stroke
• Cerebrovascular Disorders
• Ischemic Stroke

Locations

Country	Name	City	State
Switzerland	Centre hospitalier Vaudois	Lausanne	Vaud
Switzerland	Ospedale Regionale di Lugano	Lugano	Ticino

Sponsors (2)

Lead Sponsor	Collaborator
Dr. med. Carlo Cereda	Ente Ospedaliero Cantonale, Bellinzona

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.	Diagnostic performance according to PREDISC scale	1 year